Changing the future of Oncology.
About Sutro Biopharma
Sutro Biopharma is a clinical stage company pioneering a compelling and unique way of discovering, developing and manufacturing therapeutics. Our focus is aimed primarily on next generation cancer and autoimmune therapeutics — antibody conjugates, bispecific antibodies and cytokine derivatives. Unconstrained by traditional methods of cell-based discovery, we can design and develop targeted medicines by innovating outside the constraints of the cell.
Precision protein engineering generates superior molecules
3 product candidates in the clinic as a result of research innovations
Great people making excellence happen, every day!
Our technology enables us to iteratively discover and test molecules in a rapid cycle of weeks rather than months, to rapidly identify optimal molecules designed for safety and potency.
Sutro Biopharma to Host a Virtual KOL Event to Provide Clinical Update on Antibody-Drug Conjugate STRO-002 in Ovarian Cancer
– Discussion of STRO-002 Data and Program Expansion at 5pm ET / 2pm PTon Dec. 3rd – SOUTH SAN FRANCISCO, Calif., Nov. 24, 2020 – Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the...
Sutro Biopharma Announces the Appointment of Diana Landa as Vice President of Regulatory Affairs and Annie Chang as Head of Investor Relations
SOUTH SAN FRANCISCO, Calif., Nov. 18, 2020 – Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation oncology...
SOUTH SAN FRANCISCO, Calif., Nov. 11, 2020 – Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development, and manufacturing company, today announced that Chief Executive Officer, Bill Newell, will participate in four upcoming virtual conferences...